NovoStent has completed enrollment in the European clinical trial evaluating the use of SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.
NanoViricides has signed a ‘Master Service Agreement’ with the Southern Research Institute (Southern Research), Birmingham. The agreement will allow Southern Research to perform testing of the company’s anti-Influenza
Icagen has announced a one year extension to a prior collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium
Abbott has released long-term data for the SPIRIT III pivotal US clinical trial, which demonstrated that the observed clinical advantages of XIENCE V Everolimus Eluting Coronary Stent System
Impax Laboratories has initiated a challenge of the patents listed by Galderma Laboratories, in connection with its ORACEA (doxycycline) delayed-release capsules, 40mg. Impax filed its Abbreviated New Drug
Amgen has announced detailed results from a phase 3 trial evaluating denosumab administered subcutaneously versus Zometa (zoledronic acid) administered as an intravenous infusion in the treatment of bone
Anavex Life Sciences has announced the completion of scale-up manufacturing of ANAVEX 2-73, its compound for the treatment of Alzheimer’s disease. Herve de Kergrohen, CEO of Anavex, said:
Galderma and Ipsen have announced that Azzalure (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization
Glenmark Pharmaceuticals, a research-driven, global, integrated pharmaceutical, has said that it will raise INR12 billion. The company will raise the amount from overseas markets or by private placement
Valeant Pharmaceuticals has provided update on the regulatory applications to the FDA and the European Medicines Agency (EMEA) for the investigational drug retigabine, a neuronal potassium channel opener
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.